jeudi 22 février 2018

Onco Actu du 22 février 2018

1. Biologie

Similarities found in cancer initiation in kidney, liver, stomach, pancreas [WUSTL]

Study Exploring Relationship Between Precursor Conditions and Multiple Myeloma [Dana-Farber Cancer Institute]

2.5 Etiologie - Gènes

Five Novel Genetic Changes Linked to Pancreatic Cancer Risk [Johns Hopkins]

3.1 Prévention - Tabac

Cigars and pipes tied to same risks as cigarettes [Reuters]

4.2 Dép., diag. & prono. - Génome

You Don't Need a Personal Genetics Test to Take Charge of Your Health [Wired]

100,000 Genomes Project hits halfway milestone [Cancer Research UK]

Forecasts of genetic fate just got a lot more accurate [MIT Technology Review]

5. Traitements

New Technique Predicts Gene Resistance to Cancer Treatments [Yale]

After-effects not necessarily reduced with robotic prostate surgery [Reuters]

5.1 Traitements - Pré-clinique

New therapeutic gel shows promise against cancerous tumors [UNC]

5.10 Traitements - Essais

Early results from clinical trials not all they’re cracked up to be, shows new research [Mayo Clinic]

Tool 'names and shames' hidden drug trials [BBC News]

5.12.10 Immunothérapies - Fusions et acquisitions

Merck inks $394M takeover of oncolytic virus play Viralytics [FierceBiotech]

MSD poised to acquire viral immuno-oncology firm Viralytics for $394m [Pharmafile]

Merck Does a Fine Deal, But Not the One It Needs [Bloomberg]

Merck to buy Australian viral immuno-oncology firm for $394 million [Reuters]

The I/O 2.0-combo tech race is on: Merck bags oncolytics player Viralytics in $394M buyout [EndPoints]

5.12.2 Immunothérapies - CAR-T

Medigene gets OK for first trial of T-cell receptor therapy [FierceBiotech]

Doctors In China Lead Race To Treat Cancer By Editing Genes [NPR]

bluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress [bluebird bio]

5.12.5 Immunothérapies - Pharma

Arcus Biosciences eyes $100M IPO [FierceBiotech]

5.2 Pharma

Bayer announces publication of larotrectinib data in The New England Journal of Medicine [Bayer]

5.2.3 Pharma - économie

The good, the bad and the ugly for the top 15 spenders in the global drug R&D business: 2018 [EndPoints]

5.6 ESMO

TAT International Congress 2018: the Home of Phase I in Oncology [ESMO]

6. Lutte contre les cancers

India doctors remove world's 'largest brain tumour' [BBC News]

6.3 Associations/Fondations

American Cancer Society and Global Center for Medical Innovation Partner to Accelerate Pace of Bringing Research to Clinic [ACS]

6.6 Publications

ORCID Mandate Trial at Springer Nature [ORCID]

Academics Protest China’s Censorship Requests [The Scientist]